Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non–Small-Cell Lung Cancer

This publication has 40 references indexed in Scilit:

• Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
  New England Journal of Medicine, 2012
• Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
  New England Journal of Medicine, 2012
• Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells
  Lung Cancer, 2012
• The PDL1-PD1 Axis Converts Human T _H 1 Cells into Regulatory T Cells
  Science Translational Medicine, 2011
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
  The Lancet Oncology, 2011
• Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule
  Breast Cancer Research, 2010
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
  Journal of Experimental Medicine, 2009
• Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
  Clinical Cancer Research, 2009
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004